[CAS NO. 355025-13-7]  Ki16198

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [355025-13-7]

Catalog
HY-18641
Brand
MCE
CAS
355025-13-7

DESCRIPTION [355025-13-7]

Overview

MDLMFCD23704182
Molecular Weight488.98
Molecular FormulaC24H25ClN2O5S
SMILESO=C(OC)CCSCC1=CC=C(C2=C(NC(OC(C3=CC=CC=C3Cl)C)=O)C(C)=NO2)C=C1

For research use only. We do not sell to patients.

Summary

Ki16198 is a potent and orally active LPA receptor antagonist, the methyl ester of Ki16425 (HY-13285). Ki16198 inhibits LPA 1 and LPA 3 -induced inositol phosphate production with K i values of 0.34 μM and 0.93 μM, respectively. Ki16198 is effective for pancreatic cancer tumorigenesis and metastasis in vivo [1] .


IC50 & Target

Ki: 0.34 μM (LPA1 receptor)
Ki: 0.93 μM (LPA1 receptor) [1]


In Vitro

Ki16198 (0-10 μM; 48 hours) is effective to inhibit migration and invasion responses to LPA with a potency similar to that of Ki16425. The inhibitory effects Ki16198 on the invasion response to LPA, but not to EGF in several pancreatic cancer cell lines, including Panc-1,CFPAC-1, and BxPC-3 cells [1] .
Ki16198 (10 μM; 48 hours) signifivcantly decreases expression of proMMP-9 protein and mRNA expression in YAPC-PD cells [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

Ki16198 (oral administaion; 1 mg in 500 ul; 28 days) significantly decreases the degree of metastasis activity in Ki16198-treated mice. Similiar to liver, metastasis to lung and brain in mice is also observed [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male BALB/c nude mice (6 weeks old) [1]
Dosage: 1 mg in 500 ul
Administration: Oral administaion; 28 days
Result: Inhibited lung and liver metastasis in vivo.

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 204.51 mM ; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.0451 mL 10.2254 mL 20.4507 mL
5 mM 0.4090 mL 2.0451 mL 4.0901 mL
10 mM 0.2045 mL 1.0225 mL 2.0451 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: 2.5 mg/mL (5.11 mM); Suspended solution; Need ultrasonic

  • 2.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (5.11 mM); Suspended solution; Need ultrasonic

  • 3.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.5 mg/mL (5.11 mM); Clear solution

* All of the co-solvents are available by MCE.